Australasian Menopause Society - Studies Recruiting

Home

Studies Recruiting

Research studies that are related to menopause and midlife women's health may be undertaken by Australasian Menopause Society members.

Women who would like to volunteer to participate in any study outlined below should contact the nominated person from the study directly.

Disclaimer

The list of studies currently recruiting is published by the Australasian Menopause Society as a service to its members. The AMS accepts no responsibility for the accuracy of the information contained in the description of the studies or the consequences of any person becoming a study subject. These studies are not endorsed by the AMS, however all listed studies have produced Ethics Committee approval prior to being accepted for inclusion on the AMS website.

Treatment for hot flushes associated with menopause

Study Title:

Treatment for hot flushes associated with menopause.

Description of the study:

MK-6913 is a new drug being developed as a treatment for hot flushes associated with menopause. MK-6913 may represent an improvement over conventional oestrogen therapy, thereby avoiding some of the unwanted side effects of the conventional oestrogen treatement. Women will be required to take daily tablets and record hot flushes on an electronic diary. Participants will visit the study doctor 5 times during the ten week study period.

Inclusion criteria:

You may qualify for this study if you: - are a post menopausal woman between 35 and 60 years of age - have 50 moderate-to-severe hot flushes per week

Ethics Approval:

Bellberry Human Research Ethics Committee Reference No B200/09 8 March 2010

Geographical location of study:

Brisbane

Principal Investigator (AMS Member):
Dr Rae Leibowitz (PI), Dr Robyn Hüttenmeister (Co-investigator)

Contact details:
AusTrials Ground Floor, 19 Lang Parade AUCHENFLOWER QLD 4066 Ph: 07 3338 5555 Fax: 07 3338 5558

Content updated 5 May 2010

Last Updated (Monday, 05 July 2010 15:46)

International Breast Cancer Intervention Study II

Description

The International Breast Cancer Intervention Study II (IBIS II) is the first study to investigate whether the breast cancer treatment drug anastrozole can prevent breast cancer from occurring in postmenopausal women at higher risk of developing the disease. There are currently 21 countries around the world participating in this study. 10,000 women are needed worldwide and accrual passed 5100 in December 2009. Women will be required to take a daily tablet for five years and visit a clinic twice in the first year and once every year following.

The study is coordinated in Australia and New Zealand by the Australian New Zealand Breast Cancer Trials Group. The ANZ BCTG is a not-for-profit organisation and is Australia's national organisation dedicated to breast cancer research

Inclusion Criteria

Aged between 40 and 70
Postmenopausal
At increased risk of breast cancer due to a family history or other risk factors
Must not have had invasive breast cancer
Women who have had DCIS diagnosed within the last 6 months may be eligible to join a sub-study of IBIS-II, investigating treatments for DCIS.

Geographical Location of Study

The study is currently available at 28 sites in Australia and 4 sites in New Zealand.

Principal Investigator

Australia and New Zealand - Study Chairman Professor John Forbes, Study Co-Chairman Professor John Simes. Each site has its own dedicated Principal Investigator.

Contact Details

Women who are interested in participating in this study should contact the relevant freecall number and leave their details. A study coordinator from their nearest site will contact them.

Australia – 1800 640 709
New Zealand – 0800 888 656
Visit www.anzbctg.org for further information.

Last Updated (Thursday, 21 January 2010 18:09)

Oestrogen Cognition Study

Description

The aim of this project is to look at the short term effects of a drug containing oestrogen and progestin on memory changes that occur at midlife and to identify what areas of reasoning and perception are most affected. This study will also look at the effects of this medication on weight and blood pressure. The study will be run over 6 months and involves taking an oral hormone replacement therapy or placebo for this period. Participation will involve 4 visits to the study centre where Cognition (memory) testing will be performed and additional testing of a functional MRI scan at the beginning and the end of the study.

Inclusion Criteria

Aged between 45 and 55
Healthy
Postmenopausal
Right handed
Not taking hormone therapy
Able to take oral oestrogen

Ethics Approval

Monash University Standing Committee on Ethics in Research Involving Humans (SCERH).

Project Number : CF08/1572 - 2008000801

Geographical Location of Study

Monash Medical School, Alfred Hospital, Commercial Road, Prahran, Victoria 3181

Principal Investigator

Professor Susan Davis

Contact Details

Women who are interested in participating in this study should contact

Corallee Morrow and Jenny Adams

Phone: (03) 9903 0836 or (03) 9903 0833

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

http://womenshealth.med.monash.edu.au/

Content Updated 10 July 2009

Last Updated (Friday, 10 July 2009 22:53)